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A B S T R A C T
Propionibacterium acnes is a commensal bacterium, which is involved in acne inflammation. An antimicrobial
peptide named CEN1HC-Br, which was isolated and characterized form the green sea urchin, has been shown to
possess broad-spectrum antibacterial activity. Little is known concerning the potential effects of its antibacterial
and anti-inflammatory properties against P. acnes. To examine the potency of CEN1HC-Br in acne treatment, we
conducted experiments to analyze the antibacterial and anti-inflammatory activities of CEN1HC-Br both in vitro
and in vivo. The antimicrobial activity of CEN1HC-Br was evaluated by minimal inhibitory concentration (MIC)
assays using the broth dilution method. To elucidate the in vitro anti-inflammatory effect, HaCaT cells and
human monocytes were treated with different concentration of CEN1HC-Br after stimulation by P. acnes. The
expression of TLR2 and the secretion of the pro-inflammatory cytokines IL-6, IL-8, IL-1β, TNF-α, IL-12, re-
spectively, were measured by enzyme immunoassays. An evaluation of P. acnes-induced ear edema in rat ear was
conducted to compare the in vivo antibacterial and anti-inflammatory effect of CEN1HC-Br, the expression of IL-
8, TNF-α, MMP-2 and TLR2 was evaluated by immunohistochemistry and real time-PCR. CEN1HC-Br showed
stronger antimicrobial activity against P. acnes than clindamycin. CEN1HC-Br significantly reduced the ex-
pression of interleukin IL-12p40, IL-6, IL-1β, TNF-α and TLR2 in monocytes, but they were not influenced by
clindamycin. Both CEN1HC-Br and Clindamycin attenuated P. acnes-induced ear swelling in rat along with pro-
inflammatory cytokines IL-8, TNF-α, MMP-2 and TLR2. Our data demonstrates that CEN1HC-Br is bactericidal
against P. acnes and that it has an anti-inflammatory effect on monocytes. The anti-inflammatory effect may
partially occur through TLR2 down-regulation, triggering an innate immune response and the inhibition of pro-
inflammatory cytokines.
1. Introduction
Acne (Acne vulgaris) is a common dermatologic disorder.
Approximately 85% of all individuals experience acne to some degree
during the adolescence. Acne can have profound psychosocial effects
and may undermine self-confidence and self-esteem at a vulnerable
time in life [11].
Acne is a multifactorial chronic inflammatory disease of the pilo-
sebaceous duct, including non-inflammatory open and closed come-
dones and inflammatory papules, pustules, nodules, and cysts. Lesions
may be present on the face, neck, chest, or back-areas with the greatest
density of pilosebaceous units [4]. Acne has four main pathogenetic
mechanisms: abnormal keratinocyte proliferation and desquamation
that leads to ductal obstruction, androgen driven increase in sebum
production, proliferation of Propionibacterium acnes, and the products
of inflammation [1]. The crucial steps for control of acne are to avoid P.
acne colonization and inflammation in the pilosebaceous units.
Due to better understanding of the pathogenesis of acne, many anti-
acne agents are in use for acne treatment (reviewed by Leyden [28]).
Topical treatments (such as benzoyl peroxide and retinoids), topical
antibiotics (such as erythromycin and clindamycin), and systemic
therapies (such as oral antibiotics, oral retinoids and hormonal therapy)
are used for acne treatment today. However, the main limitation is that
these agents can induce irritant dermatitis [3,9], induce bacterial re-
sistance [18], or be associated with gastrointestinal disturbance [40]
and so on. Although the therapies mentioned above are still commonly
https://doi.org/10.1016/j.peptides.2017.11.001
Received 2 July 2017; Received in revised form 30 October 2017; Accepted 1 November 2017
⁎ Corresponding authors.
E-mail addresses: chenghao1@zju.edu.cn, hr_hz@163.com (H. Cheng), Chun.Li@uit.no (C. Li).
Abbreviations: CEN1HCBr, the brominated heavy chain of centrocin 1; MIC, minimal inhibitory concentration; IL, interleukin; TNF, tumor necrosis factor; TLR, Toll-like receptor; MMP,
matrix metalloproteinase; AMPs, antimicrobial peptides; LPS, lipopolysaccharides
Peptides 99 (2018) 36–43
Available online 03 November 2017
0196-9781/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
T
employed to treat acne, safer and more efficient agents are strongly
needed.
Recently, more light has been thrown on antimicrobial peptides
(AMPs), which can be candidates for acne treatment. AMPs are rela-
tively short amino acid sequences, usually less than 100 amino acids
(aa) [12,32]. The sequences commonly contain many positive charged
residues such as arginine and lysine, which help to form the net positive
charge of cationic AMPs [14,47]. Many antimicrobial peptides fold into
an amphipathic structure, which reflects the relative abundance and
polarization of hydrophobic and hydrophilic domains in their con-
formational structures. The hydrophobicity assists water-soluble anti-
microbial peptides to interact with the hydrophobic lipid bilayer of the
cell membrane. These fundamental features of AMPs also determine
their antimicrobial properties. Furthermore, there is evidence that
AMPs have multiple roles, not only a direct antimicrobial function but
also an indirect modulation of innate immunity, such as modulation of
the expression of chemokines/cytokines, and influencing the processes
of apoptosis, angiogenesis, and wound healing (reviewed by Hilchie
et al. [16]).
Centrocin1 is a heterodimeric peptide which consists of a bromi-
nated heavy chain (30 aa, CEN1HC-Br) and a light chain (12 aa,
CEN1LC) linked by an internal disulfide bond [30]. It was shown that
CEN1HC-Br contributes to the antimicrobial activity while the CEN1LC
did not seem to influence activity against microbes. Furthermore, it has
been demonstrated that 6.3–12.5 mg/L of the debrominated version of
the heavy chain (CEN1HC) was able to kill ≥99% of P. acnes ATCC
6919 in 0.037% BHI broth and 50% heat inactivated simulated wound
fluid, respectively [2]. It was also shown that the heavy chain of cen-
trocin1 reduced the release of inflammatory cytokine TNF-α and IL-6 in
LPS-stimulated cell line THP-1. The above striking results of CEN1HC-
Br motivate us to investigate whether CEN1HC-Br can be used as der-
matological agents for treatment of acne disease.
In this study, CEN1HC-Br was examined for its effect against acne
related bacterial pathogens including a couple of clinical isolates,
especially clindamycin resistant strains. The anti-inflammatory activity
of CEN1HC-Br was also studied in two types of cells. It was shown that
CEN1HC-Br could inhibit the expression of TLR2 and cytokines such as
TNF-α, IL-1β, IL-6. In addition, an animal model was used to investigate
anti-inflammatory effects of CEN1HC-Br in vivo. We found that
CEN1HC-Br attenuated P. acnes caused tissue swelling, TLR2 expres-
sion, and cytokines expression such as IL-8, TNF- α, MMP-2. These
results suggested that CEN1HC-Br has drug potency for acne treatment.
2. Materials and methods
2.1. Peptide synthesis and antibiotics
The brominated heavy chain of centrocin 1 (CEN1HC-Br,
FKKTFHKVSHAVKSGIHAGQRGCSA LGF) was purchased from BIOMOL
International LP (Exeter, UK), which were synthesized by using Fmoc
solid phase technology. The content and purity of peptides were de-
termined by high performance liquid chromatography (HPLC) and mass
spectrometry (MS) analysis. Clindamycin phosphate, which has been
used clinically in acne treatment for a long time [7], served as a positive
control.
2.2. Preparation of bacteria
Strains of P. acnes (ATCC 6919), S. epidermidis (ATCC 12228) and
S. aureus (ATCC 25913) were ordered from American Type Culture
Collection. Fifteen strains of P. acnes were clinically isolated from pa-
tients with acne vulgaris at Sir Run Shaw hospital of Zhejiang
University. All patients have no history of topical antibiotic treatment.
The strains of P. acnes were cultured in Brucella agar supplemented
with hemin (5 μg/ml; Sigma, St. Louis, Mo), Vitamin K1 (1 μg/ml;
Sigma, St. Louis, Mo), and lysed horse blood (5% v/v; Shanghai, China)
at 37 °C under an anaerobic atmosphere using MGC Anaeropack sys-
tems (Mitsubishi, Gas Chemical Co., Inc, Japan), respectively. P. acnes
was cultured to the exponential phase for 2 days and to the stationary
phase for 3–4 days. For antimicrobial testing P. acnes was then grown
in Brain Heart Infusion broth (BHI broth; Sigma-Aldrich, USA). S. epi-
dermidis (ATCC12228) and S. aureus (ATCC 25913) were grown in
Mueller-Hinton Broth (MHB; Difco Laboratories, Detroit, MI).
2.3. In vitro antimicrobial testing
Minimal inhibitory concentration (MIC) of CEN1HC-Br and clin-
damycin phosphate was determined as the lowest concentration of test
samples that completely inhibit bacterial growth, which was measured
by optical density. Briefly, samples were prepared as a stock solution in
0.9% salt water and then twofold serially diluted. Ninety microliter of
the broth (BHI broth for P. acnes, MH broth for S. epidermidis, and S.
aureus), 10 μl of the bacterial suspension (107 CFU/ml) and 10 μl of the
test sample were added together into a well of sterile 96-well microtitre
plates and incubated under anaerobic conditions at 37 °C for 96 h for P.
acnes and under aerobic conditions at 37 °C for 48 h for S. epidermidis
and S. aureus. The optical density of cultures was measured at 600 nm
by a microplate reader to estimate bacterial growth.
2.4. Cells
Monocytes from healthy donors were obtained from peripheral
blood mononuclear cells (PBMC). PBMC were purified from buffy-coats
(obtained from Blood Donation Center in Zhejiang, China) using a
density gradient (Ficoll-Paque, Pharmacia, Glattbrugg, Switzerland).
Monocytes were sorted from PBMC using anti-CD14-labeled magnetic
beads (MACS, Miltenyi Biotech, Bergisch-Gladbach, Germany) ac-
cording to the manufacturer’s instructions, and were grown in RPMI
medium with 10% fetal bovine serum.
HaCaT cells were grown in DMEM high glucose medium (4.5 g/L,
Invitrogen, Basel, Switzerland), supplemented with 2 mM L-glutamine
and 10% fetal bovine serum (Invitrogen, Basel, Switzerland).
2.5. Cell viability assay
Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Japan) was used
to assess the rate of cellular proliferation and quantify cell viability. In
brief, HaCaT cells or monocytes were seeded in 96-well plates with 100
μl of medium at a density of 2 × 104 cells per well. After incubation of
cells with CEN1HCBr, 10 μl of CCK8 solution was applied to each well
and incubated for 1 h at 37 °C. Finally, the absorbance values at 450 nm
were determined using a microplate reader (FLX800TBID, BioTek
Instruments, Winooski, VT). All experiments were conducted in tripli-
cate.
2.6. In vitro anti-inflammatory effect
Cultured HaCaT cells, which were propagated to at least 70% con-
fluence, or monocytes were challenged with P. acnes (ATCC6919) at
1 × 106 CFU. After the cells were incubated with P. acnes for 1 h,
CEN1HC-Br or clindamycin was added to each well at various con-
centrations (0.5, 1, 5, 10, 50 or 100 mg/L). To determine the expression
level of cytokines, supernatants of monocytes or HaCaT cells were
collected at 48 h after the addition of CEN1HC-Br or clindamycin. The
following cytokines were determined: IL-8, IL-6, IL-1β and TNF-α for
monocytes, IL-12p40 for HaCaT cells and monocytes. An enzyme-linked
immunosorbent assay kit (R&D Systems, Minneapolis, MN) for each
cytokine was used to determine the expression level of cytokines ac-
cording to the manufacturer’s instructions. All experiments were per-
formed three times independently.
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2.7. In vivo anti-P. acnes experiments
2.7.1. Animal treatment
P. acnes (ATCC6919) was grown to the exponential-phase in bru-
cella agar and then resuspended in 0.9% saline (5 × 108 CFU/ml).
Twenty-four female Sprague-Dawley rats (aged 3–5 weeks, weight
100–120 g) were purchased from Zhejiang Experimental Animal
Center. The animals were divided into three experimental groups of
eight animals each. P. acnes solution (10 μl) was intradermally injected
into left ears of the animals. Right ears of the animals received the same
volume of 0.9% salt water. The dose of clindamycin was based on
previously reported efficacy [13]. 1000 mg/L clindamycin, 500 mg/L
CEN1 HC-Br or normal saline was applied on the surface of left ear skin
once per day after injection with P. acnes or saline. After bacterial in-
jection for 24 h, ear thickness was measured using a microcaliper.
To investigate the therapeutical effect, the change of ear thickness
was determined continuously from day 11 to day 14 using a vernier
calliper. The granulomatous inflammation remains constant from the
6th day to 14th day. The rats were maintained at the animal facility at
Zhejiang University.All the experimental protocols to use animals were
performed under minimized suffering and approved by the Animal Care
and Use Committee at Zhejiang University.
2.7.2. Histopathology and immunohistology check
Ears of animals were excised and fixed in neutral-buffered 10%
formalin solution and embedded in paraffin. The slides were cut at
approximately 4 μm and examined with haematoxylin and eosin
staining as well as immunohistochemistry for anti-rat TLR2 antibodies
(Rockland Immunochemicals, Gilbertsville, PA), TNF-α and MMP-2
antibodies (Abcam, Cambridge, United Kingdom,). Immunoperoxidase
staining sections were acetone fixed and blocked with normal horse
serum before incubation with the mAbs for 60 min, followed by bioti-
nylated horse anti-mouse IgG for 30 min. Primary Abs were visualized
with the ABC Elite system (Vector Laboratories, Burlingame, CA),
counterstained with hematoxylin, and mounted in aqueous dry
mounting medium (Crystal Mount; Biomeda). Under a 400 × magni-
fication light microscope, TLR2+ cells, TNF-α+ cells and MMP-2+ cells
were recorded as cells with brown staining in the cytoplasm. For each
slide, five random fields that mainly contained papillary dermis were
selected, and the number of positive dermal cells and the total number
of dermal infiltration cells in each field were counted. Positive cell
density is the ratio of total number of positive cells in five fields divided
by total number of cells in five fields.
2.7.3. Real-time polymerase chain reaction (RT-PCR) measurement of
inflammatory markers
Ears of rats were injected with live P. acnes (ATCC 6919) as described
above. Both ears of the rat were excised on day 15 after bacterial in-
jection respectively, and then homogenized in 0.9% salt water (1 ml per
ear biopsy) with a hand tissue grinder. RT-PCR was performed with
amplification kits purchased from TAKARA and Applied Biosystems (Life
technologies, Sydney, Australia). Total RNA was extracted using TRIzol
Reagent (Molecular Research Center, Inc., Cincinnati, OH) according to
the manufacture’s instruction. After initial denaturation at 94 °C for 15 s,
amplification was performed for 40 cycles at 95 °C for 5 s, 60 °C for 30 s.
All 24 samples were tested for RT-PCR analysis of TNF-α, IL-8, TLR2 and
MMP-2 (Primers were listed in Table 1).
2.8. Statistical analysis
One-way ANOVA was used for statistical analyses. Results are expressed
as means ± standard errors of the mean. GraphPad (version 5) was used to
calculate p values: ***, extremely significant, p < 0.001; **, very sig-
nificant, p= 0.001–0.01; *, significant, p = 0.01-0.05; and ns, p > 0.05.
3. Results
3.1. Antimicrobial activities of CEN1HC-Br against skin bacteria
To determine antibacterial effects of CEN1HC-Br against skin bac-
teria, threestrains of common skin bacteria and fifteen clinical isolates
of P. acnes were chosen for the test. As listed in Table 1, CEN1HC-Br
showed strong antimicrobial activities against the tested P. acne strains.
Both, peptide and clindamycin, were active against P. acnes ATCC6919
with a MIC value of 4 mg/L. However, CEN1HC-Br, proved more active
than clindamycin against fifteen clinically isolated P. acnes strains. The
lowest MIC value is 0.125 mg/L. Concentrations of 4–16 mg/L can even
inhibit the growth of clindamycin resistant strains (Table 2). This
suggests that CEN1HC-Br has stronger anti-P. acne activity than clin-
damycin in vitro. CEN1HC-Br also showed antimicrobial activity with a
MIC of 32 mg/L against Staphylococcus. aureus ATCC 25913, while
clindamycin had no activity even at 512 mg/L. In addition, CEN1HC-Br
inhibited the growth of S. epidermidis ATCC 12228 at 16 mg/L, while
the MIC value of clindamycin was 64 mg/L.
3.2. Cytotoxic assays
Human keratinocytes, which are a major cell type in the epidermis,
were used to investigate the cytotoxic effects of CEN1HC-Br. In addition
the viability of human monocytes was used to evaluate the cytotoxicity
of CEN1HC-Br. We found that monocytes were about 95% viable
Table 1
Primer list of RT-PCR.
Name Sequence
TNF-α forward 5′ CGTCAGCCGATTTGCCATTT
TNF-α reverse 5′ TCCCTCAGGGGTGTCCTTAG
MMP-2 forward 5′ AGGGCACCTCTTACAACAGC
MMP-2 reverse 5′ CCCGGTCATAATCCTCGGTG
IL-8 forward 5′ ACTCAAGAATGGTCGCGAGG
IL-8 reverse 5′ ACGCCATCGGTGCAATCTAT
TLR-2 forward 5′ TGGAGGTCTCCAGGTCAAATC
TLR-2 reverse 5′ TGTTTGCTGTGAGTCCCGAG
GAPDH forward 5′ CAAGTTCAACGGCACAGTCA
GAPDH reverse 5′ CACCCCATTTGATGTTAGCG
Table 2
MIC (mg/L) of CEN1HC-Br and clindamycin against P. acne strains.
ATCC
6919
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
CEN1HC-Br 4 0.125 4 8 2 16 2 8 32 4 16 16 16 16 16 0.125
Clindamycin 4 0.125 * * 4 * 16 128 4 16 * * * 64 64 0.125
MIC was defined as the lowest concentration of test samples that completely inhibit microorganism growth. *MIC value
is> 512mg/L. The clindamycin resistant strains are highlighted with gray.
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incubated with CEN1HC-Br at concentrations from 2 to 400 mg/L
(Fig. 1). Further, although CEN1HC-Br exerted little effects on HaCaT
cell viability at 400 mg/L (viability changed from 98.8% to 89.4%),
CEN1HC-Br had no impact on cell viabilities from 2 to 200 mg/L. These
results indicate that use of CEN1HC-Br does not result in any significant
cytotoxicity against HaCaT cells or monocytes even at concentrations
more than tenfold higher than necessary for antibacterial activity
against P. acnes.
3.3. Effects of CEN1HC-Br on proinflammatory cytokines in vitro
It is known that P. acnes elicit an inflammatory response in acne
vulgaris. The inflammation of infected human monocytes by P. acnes
results in the activation of TLR2, which leads to the release of a wide
variety of proinflammatory cytokines such as IL-6, IL-1β, IL-8, and TNF-
α through the NF-κB signaling pathway [22]. To examine whether
CEN1HC-Br has an immunomodulatory effect, we examined the ex-
pression of TLR2, IL-8, IL-6, IL-1β, TNF-α and IL-12p40 in P. acnes-
stimulated monocytes. We found that the expression of TLR2 was in-
creased two-fold in monocytes after P. acnes inoculation for 48 h (data
not shown). Importantly, this overexpression of TLR2 was significantly
down-regulated by co-treatment with CEN1HC-Br and the effect was
dose-dependent (Fig. 2A). Although clindamycin also inhibited the
Fig. 1. Cytotoxicity of CEN1HC-Br on human HaCaT cells and monocytes. Each value
represents the mean of three individual experiments.
Fig. 2. Inhibitory effects of CEN1HC-Br and clindamycin on TLR2 (A), IL-8 (B), IL-6 (C), IL-1b (D), TNF-α (E) and IL-12p40 (F) secretion in human monocytes. Data represent mean±SE
of three individual experiments.
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expression of TLR2, the effect was not dose-dependent. Further, the
production of IL-6, IL-1β, IL-10, TNF-α and IL-12p40 in P. acnes-in-
duced monocytes was also inhibited by CEN1HC-Br in a dose-depen-
dent manner (Fig. 2B–F). For example, P. acnes-induced monocytes
incubated with 0.5 mg/L, 1 mg/L, 5 mg/L, 10 mg/L, 50 mg/L, and
100 mg/L of CEN1HC-Br resulted in 88% ± 0.3%, 81% ± 3.8%,
75% ± 7.9%, 47% ± 12.5%, 41% ± 11.6%, 19.8% ± 3.4% in-
duced IL-8 secretion compared to the positive control, respectively,
while 0.1 mg/L of peptide did not show any inhibition. Although clin-
damycin exerted a reduction of inflammatory cytokines including IL-8,
IL-6, IL-1b, TNF-α and IL12p40 in human monocytes, this effect was not
significant.
3.4. Effects of CEN1HC-Br on P. acnes-induced inflammation in vivo
3.4.1. Histopathology and immunohistology check
Ear swelling induced by P. acnes challenge was observed as illu-
strated in Fig. 4 Seven days post injection (dpi) of P. acnes, visible ear
swelling of bacterial challenged rats was three times thicker than the
ears challenged with saline (the blank control). No swelling was ob-
served in blank control group. All rats were recovered gradually. At 11
dpi to 14 dpi, the ear thickness of rat only using the vehicle as the
treatment control was 279% ± 41.1%, 240% ± 35.8%,
190% ± 32.7%, and 149% ± 37.3% of that of the blank control
while that of CEN1HC-Br treated group was 224% ± 34.8%,
197% ± 34.2%, 130% ± 25.5%, and 102% ± 28.1% of that of the
blank control, respectively. For the positive group (clindamycin-
treated), the thickness of ear was 245% ± 36.9%, 202% ± 40.4%,
153% ± 32.3%, and 114% ± 21.1% of that of the blank control, re-
spectively. Both treatment with CEN1HC-Br and clindamycin exhibited
significant reduction of ear swelling (P < 0.01), but no significant
difference between these two treatments.
To further evaluate the anti-inflammatory effect of CEN1HC-Br in
vivo, a histological check was conducted (Fig. 3). Comparison of Fig. 3A
and B illustrates that the ear inflammation and swelling in the ear tissue
of the experimental rat was induced significantly by intradermally in-
jected P. acnes. Many infiltrated inflammatory cells could be found at the
bacterial injection site. After epicutaneous application of CEN1HC-Br
solution on the rat ear for 14 days, the inflammation was ameliorated
effectively, and the number of infiltrated inflammatory cells decreased
markedly (Fig. 3C). However, the treatment control group (with vehicle)
did not show a reduction of ear swelling. The positive control treated
with clindamycin inhibited the ear inflammation induced by bacterial
injection and decreased infiltrated inflammatory cells (Fig. 3D), while its
therapeutic potency was less than that of CEN1HC-Br.
To investigate whether P. acnes induces a change of expression of
TLR2, TNF-α, and matrix metalloproteinase 2 (MMP-2), the expression
of TNF-α, MMP-2 and TLR2 in the challenged rat ear skin was further
evaluated by immunohistochemistry. Immunohistochemistry labeling
using a specific anti-rat antibody against TNF-α, MMP-2, and TLR2
revealed that the number of TNF-α, MMP-2, and TLR2 positive cells
apparently increased in the ear skin of the experimental rat (Fig. 4).
After epicutaneous application of CEN1HC-Br or clindamycin solution
on the rat ear for 14 days, the expression of TNF-α, MMP-2 and TLR2
was decreased significantly, while there was no significant difference
between the CEN1HC-Br and clindamycin group by im-
munohistochemistry according to the quantitative analysis of stained
positive cells (Fig. 5).
3.4.2. Realtime-PCR measurement of inflammatory markers
To determine whether the transcription of the pathogen recognition
receptor and proinflammatory cytokines is mediated by CEN1HC-Br, we
used real-time PCR to measure the effects of CEN1HC-Br on the ex-
pression of TLR2, MMP-2, TNF-α and IL-8. We found that both the
expression of MMP-2 and IL-8 in the CEN1HC-Br group is significantly
lower than in the clindamycin group and control (P < 0.05), while the
expression of TNF-α of the CEN1HC-Br group is lower than of the
clindamycin and control group but without statistical significance
(Fig. 6). The expression of TLR2 in the CEN1 HC-Br and clindamycin
group is significantly lower than control group (P < 0.05).
4. Discussion
A strong demand motivates research scientists and pharmaceutical
companies to seek safer and more effective agents to treat acne, espe-
cially agents avoiding antibiotic resistance development. It has been
shown that topical erythromycin and clindamycin treatment could lead
to a gradual increase in antibiotic resistance [17], which results in the
failure of antibiotic treatment for acne. The horizontal gene transfer
allows the antibiotic resistant genes to further spread to other poten-
tially pathogenic bacterial species and/or strains [29]. Currently, AMPs
as a novel group of antimicrobial agents attract more attention to de-
velop an alternative acne treatment [15]. Several antimicrobial pep-
tides (AMPs) are related with the infection of acne vulgaris. It has been
Fig. 3. Histopathology analysis of SD rat ears after epicutaneous appli-
cation of vehicle (B), CEN1HCBr (C) or clindamycin (D) for 14 days. (A)
Rat ear injected with only 0.9% saline. (B, C, D) The ears of experimental
rats were intradermally injected with P. acnes. P. acnes significantly in-
duced dermis tissue inflammation and swelling as illustrated in (B). Many
infiltrated inflammatory cells could be found in the injection site of P.
acnes. After epicutaneous application of 500 mg/L CEN1HCBr solution on
the rat ear for 14 days, the inflammation induced by P. acnes was ame-
liorated effectively, and the number of infiltrated inflammatory cells sig-
nificantly decreased (C). The positive control 1000 mg/L clindamycin also
effectively inhibited ear inflammation induced by P. acnes injection and
decreased infiltrated inflammatory cells (D). CA, ear hyaline cartilages;
EP, epidermis; DE, dermis; MU, muscle. The arrows in the figure indicate
the thickness of the dermis layer. Scale bar = 10 μm.
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reported that the levels of hBD-2, S100A7, HNP1-3 and granulysin in-
creased in acne lesions, suggesting that they may play a protective role
in acne. Based upon the expression of AMPs induced by P. acnes, re-
searchers have been attempting to develop hBD-2, LL-37, S100A7,
RNase 7 and granulysin as therapeutics for P. acnes-mediated infection,
which individually or synergistically display antimicrobial activity
against P. acnes. However, hBD-2, LL-37, S100A7 and HNPs may ex-
acerbate inflammation through recruitment and activation of immune
cells and release of pro-inflammatory mediators [15]. Only a synthe-
sized granulysin-derived peptide has been reported to suppress P.
acnes-mediated cytokine release, regardless of the increase in the
number of comedones [31]. Dermcidin (DCD) peptides are the principal
AMPs in sweat. In contrast to the above AMPs, the expression of
dermcidin (DCD), a principal AMPs in sweat, is downregulated in the
sweat of patients with acne vulgaris. Since DCD possesses antimicrobial
activity against P. acnes, its reconstitution may also be a potential
candidate [37]. To further augment the therapeutic effect of AMP,
various exogenous and synthetic AMPs have been developed recently.
Ryu S. et al. examined the role of Helicobacter pylori-derived synthetic
antimicrobial peptide HPA3NT3 and an α-helical cationic peptide P5
against P. acnes in the skin, and their ability to block P. acnes-induced
inflammation. Both AMPs appear to be highly potential therapeutic
agent for the treatment of acne vulgaris by intradermal injection in
mice ear [41,42]. Two frog skin-derived antimicrobial peptides [D4k]
ascaphin-8 and [T5k]temporin-DRa showed potential activities in in-
hibiting the growth of P. acnes and the release of pro-inflammatory
cytokines, and in stimulating the release of anti-inflammatory cytokines
in human peripheral blood mononuclear cells [39].
A Trp–Lys-rich peptide LZ1 was screened and its antimicrobial and
anti-inflammation potential was demonstrated by Zhang Z.
Furthermore, LZ1 showed little hemolytic activity on human red blood
cells and high stability in human plasma. Topical application of LZ1 on
mice ear also showed antimicrobial effects and inhibition of the P. acne-
induced inflammation [48]. Several synthetic AMPs, such as Omiganan
and HB1345 have even entered clinical trials as an alternative treat-
ment of acne vulgaris, but have not yet been approved [38]. Translating
AMP activity from in vitro experimentation to clinical application has
been difficult due to the cost of goods, their lability to proteolytic de-
gradation, and their unknown toxicology profile when administered
systemically. In this context, we try to find a new topical usable AMP
for the treatment of acne vulgaris.
CEN1 HC-Br showed strong antimicrobial activities against S. epi-
dermidis (ATCC 12228), S. aureus (ATCC 25913), P. acnes (ATCC
Fig. 4. Immunohistochemistry of the expression of TNF-α, MMP-2, and
TLR2 on rat ears. The rat ear injected with only 0.9% saline did not show
TNF-α+ cells (A), MMP-2+ cells (C), and TLR2+ cells (E). In contrast,
numerous TNF-α+ cells (B), MMP-2+ cells (D), and TLR2+ cells (F) were
detected in the inflammatory infiltrate around the perifollicular/peri-
bulbar region 7 days after injection of P. acnes. Original magnification,
Scale bar = 10 μm.
Fig. 5. Immunohistochemistry of TLR2, MMP-2 and TNF-α. After epicutaneous applica-
tion of CEN1HC-Br, clindamycin or vehicle on the rat ear for 14 days, all the in-
flammatory markers returned to baseline levels. There is no significant difference be-
tween the CEN1HC-Br group and clindamycin group (P > 0.05). Data represent
mean ± SE of eight rats in each group. NS: vehicle group.
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6919), and also 15 clinical isolates of P. acnes. This is in agreement with
the findings of AMPs’ anti-P. acnes activity by other researchers. For
examples, 4 μM of synthetic LL-37 killed 100% of P. acnes, while 50 μg/
ml of psoriasin alone killed 95% P. acnes [26]. Granulysin is effective
against P. acnes at the concentration of 32 μM [33]. In our study, the
most striking result is CEN1 HC-Br activity against clindamycin re-
sistant strains. All tested clinical isolates of P. acnes showing clin-
damycin resistance (MIC > 512 mg/L) were susceptible to CEN1 HC-
Br (MIC range from 4 to16 mg/L, Table 1). Although we have no clues
for a variety of phenotypes of resistance, the use CEN1 HC-Br and
clindamycin to screen clinical isolates and combined with genomic
mapping of those isolates might illustrate the target molecules by CEN1
HC-Br and the development of resistance.
Another significant feature of CEN1 HC-Br is that it exerted strong
anti-inflammatory effects. Follicular colonization by P. acnes plays a
key role in the formation of acne. The proliferation of P. acnes will
attract CD4+ lymphocytes and macrophages to the microcomedone
[20] and then induce the inflammatory acne lesion with rupture of the
follicular wall. As illustrated by Fig. 3B, injection of P. acnes attracted
plenty of infiltrated inflammatory cells. After epicutaneous adminis-
tration of CEN1 HC-Br, the number of infiltrated inflammatory cells
decreased markedly (Fig. 3C), and ear swelling induced by P. acnes was
inhibited significantly, which suggested a strong anti-inflammatory
effect. As our understanding of the cutaneous microbiome and the role
of commensal bacteria in driving skin inflammation increases, ther-
apeutic targeting of P. acnes in the treatment of acne vulgaris is an area
of active research in late (inflammatory) acne lesions via the activation
of TLR2 [8]. Activation of TLR2 on monocytes releases pro-in-
flammatory cytokines, IL-6, IL-1β, IL-12 and IL-8. IL-8 attracts neu-
trophils to the site of active lesion, and triggers the release of lysosomal
enzymes by neutrophils, which leads to rupture of the follicular epi-
thelium and further inflammation [19,24]. Reduced expression of IL-8
after treatment with CEN1 HC-Br was observed in human monocytes in
ELISA (Fig. 2) and in rat ear tissue by immunohistochemistry and RT-
PCR respectively (Figs. 4–6). IL-12 is a pivotal cytokine in activating
Th1 T cell responses and is one of the major proinflammatory cytokines
produced by monocytes in response to Gram-positive organisms [45].
Overproduction of cytokines in Th1 cells such as IL-12 has been im-
plicated in the development of tissue injury in certain autoimmune and
inflammatory diseases [21]. The inhibited production of IL-12 by CEN1
HC-Br was shown in human monocytes by ELISA (Fig. 2). Meanwhile,
the ELISA results also demonstrated suppressed production of in-
flammatory cytokines including IL-6 and IL-1β in human monocytes
(Fig. 2). TNF-α and MMP-2, mediators and markers of inflammation,
were induced by the P. acnes injection, evidenced by an acute rise of
their mRNA and protein levels, reflected by the results of the
immunohistochemistry and PCR respectively (Figs. 4–6). This is con-
sistent with prior reports that P. acnes can stimulate focal secretion of
TNF-α [43]. MMPs can be induced by P. acnes either directly or by P.
acnes-induced elevation of TNF-α. [5,27]. P. acnes-derived PGN play an
aberrant role due to the enhancement of proMMP-2 production in acne
lesions via a TLR2-dependent pathway [44]. In this manner, the acti-
vation of TLR2 on monocytes is likely involved in the pathogenesis of
acne. The inhibition effect of CEN1 HC-Br on TLR2 may explain the
reduced expression of IL-6, IL-1β, IL-12, IL-8, TNF-α and MMP-2 in
monocytes.
Furthermore, since MMP-2 has higher substrate specificity to type-
IV collagen, a structural element of the basement membrane [46], the
acceleration of MMP-2 expression by P. acnes in sebaceous glands in
acne lesions is likely to result in the destruction of the basement
membrane between the epithelium and dermis, subsequently leading to
dermal extracellular matrix degradation for acne scarring. Inhibition of
MMP-2 production by CEN1 HC-Br can be effective as an anti-acne
agent for the prevention and remission of scar formations.
Clindamycin, a lincosamide antibiotic, was used as a control drug in
this study. It also exerted comparative inhibition of the expression of
TLR2, IL-8, TNF-α and MMP-2 in rat ear model (Figs. 4–6), but without
significant reduction of inflammatory cytokines including IL-8, IL-6, IL-
1b, TNF-α and IL-12p40 in human monocytes as shown by ELISA
(Fig. 2). It was consistent with previous report that clindamycin has no
inhibitory effect against the production of proinflammatory cytokines
in mononuclear cells, but down-regulate keratinocyte production of
proinflammatory cytokines and chemokines [25]. Thus, it seems to be
rational that keratinocytes have a pivotal role in initiating and po-
tentiating inflammation, and that clindamycin can interfere with the
keratinocyte activation cycle driven by P. acnes, lymphocyte and ker-
atinocyte-derived cytokines in acne vulgaris [10].
The concentrations of CEN1 HC-Br and clindamycin employed in
the present study were 0.1–100 mg/L, being similar to those needed for
antibacterial activity against P. acnes. However, drug concentrations in
the rat skin measured 4 h after a single application of CEN1HC-Br and
clindamycin solution were approximately 20 mg/kg (in wet tissue),
similar as the concentration used in the study and under the cytotoxic
concentration. Accordingly, the concentration may be achievable in
acne lesions after single topical application of these antimicrobials.
From the histopathology check of rat ear, no necrosis or abnormal
epithelial cells were seen after 15 days application of CEN1HC-Br and
clindamycin solution.
Together, our data shows that CEN1 HC-Br has antimicrobial ac-
tivity against skin bacteria in vitro and inhibits P. acne-induced TLR2
expression and subsequently downregulates inflammatory cytokines
both in vitro and in vivo. Therefore, CEN1HC-Br with its dual effects on
Fig. 6. The expression of TLR2, MMP-2, IL-8, and TNF-α mRNA was
measured using real-time RT-PCR and normalized to the expression of
GAPDH. All values are expressed as the mean ± SD. *P < 0.05. NS:
vehicle group.
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acne, might be an outstanding alternative for acne treatment. Especially
its activity against antibiotic resistant strains make it stand out from
conventional drugs.
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